简体
  • 简体中文
  • 繁体中文

热门资讯> 正文

Sagimet Biosciences在AASLD 2025上展示了Denifanstat 2b期结果,强调了晚期纤维化和生物标志物的改善

2025-11-10 20:19

  • A secondary analysis of FASCINATE-2 Phase 2 trial demonstrated denifanstat improved fibrosis, inflammation and steatosis in advanced qF4 MASH patients as measured by artificial intelligence (AI) digital pathology
  • In a second poster, spatial computational histology relying on baseline fibrosis features was used to predict response to denifanstat

风险及免责提示:以上内容仅代表作者的个人立场和观点,不代表华盛的任何立场,华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前,应结合自身情况,考虑投资产品的风险。必要时,请咨询专业投资顾问的意见。华盛不提供任何投资建议,对此亦不做任何承诺和保证。